Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BMS-844421
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Molecules, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
BMS-844421 is an antisense oligonucleotide therapeutic developed to target proprotein convertase subtilisin/kexin type 9 (PCSK9), a key regulator of cholesterol metabolism. By inhibiting PCSK9 protein synthesis at the mRNA level, BMS-844421 was designed to increase hepatic low-density lipoprotein receptor (LDLR) levels and thereby lower serum LDL cholesterol. The drug was originally discovered by Isis Pharmaceuticals (now Ionis Pharmaceuticals) and further developed by Bristol Myers Squibb for the treatment of hypercholesterolemia and atherosclerosis. Clinical development reached Phase 1 but was discontinued due to safety concerns[1][2][3][6].
02
Targets
PCSK9 (Proprotein convertase subtilisin/kexin type 9)
Beyond the preview
Go deeper on BMS-844421.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BMS-844421.